Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland. Vanda Pharmaceuticals Inc., a biopharmaceutical company, engages in the development and commercialization of clinical-stage drug candidates for central nervous system disorders. Its product portfolio includes Iloperidone (oral), a compound for the treatment of schizophrenia completed Phase III clinical trial; and Tasimelteon, which completed Phase III clinical trials for transient insomnia and chronic primary insomnia. The company's products also comprise Iloperidone (Injectible) for the treatment of schizophrenia and Tasimelteon for the treatment of depression, which are in the Phase II initiation status.

Gemini Pharmaceuticals' private label products are formulated to be as effective as their name-brand twins. The company makes prescription and OTC pharmaceuticals and nutritional supplements, including acetaminophen, vitamin B-12, and herbal enhancers. Its pharmaceutical offerings include cough and cold medications, pain relievers, and sleeping aids. Its supplement product line starts with such basics as vitamins and minerals, and then includes what it calls "specialty products" such as energy boosters and weight loss supplements. Gemini Pharmaceuticals also makes pet care supplements such as joint support and allergy relief and prescription prenatal vitamins and other custom formulations.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

DFB Pharmaceuticals makes products that protect its armor -- the skin. Through its Healthpoint subsidiary, the pharmaceutical holding company develops, acquires, and markets drug brands that prevent or treat disorders associated with skin and soft tissue. Its portfolio of more than 50 prescription and over-the-counter (OTC) products includes dermatology creams, surgical scrubbing solutions, and wound cleansers and dressings. Its DPT Laboratories subsidiary offers contract manufacturing of semi-solid and liquid drugs, while Phyton Biotech produces active pharmaceutical ingredients (APIs) for DFB and other drug makers in the area of plant-cell culture technology.

The Medical Research Council (MRC) is a not-for-profit UK government-financed organization that promotes and funds medical and other health-related research. Founded in 1913, MRC funding has been responsible for some of the biggest breakthroughs in life sciences, such as the purification of penicillin and the development of magnetic resonance imaging (MRI) technology. The council's funding is distributed to researchers in universities, the National Health System, and MRC research centers. Current research priorities include AIDS, antibiotic resistance, the use of animals in research, chronic fatigue syndrome, the study of cognitive systems, intensive care, multiple sclerosis, and other areas of public health.

CEO Samuel Bogoch founded Oncolab shortly after he discovered the technology for detecting anti-malignin antibodies in the 1960s. Oncolab, Inc. company makes the AMAS test, an early warning blood screening test for cancer. The test detects abnormal levels of anti-malignin antibody which may indicate the presence of tumors. It is the first antibody that can be directly related to the survival of cancer patients and can be easily detected even before malignin reaches a detectable level. The test is shipped for free and is administered by doctors, then sent to Oncolab to process the results (for a fee); there are also a handful of lab locations that administer the test.

BioSyntech is a development-stage company specializing in the creation and development of biotherapeutic thermogels to be used for human tissue repair and therapeutic delivery. The BST-Gels are liquid at room temperature but solidify at human body temperature, and they are classified as medical devices by the FDA and other regulators. Various products in development include BST-CarGel (cartilage repair), BST-InPod (heel cushioning), and BST-DermOn (chronic wound healing). For now, the company makes its money primarily from the sale of Ultrasan, a pure form of chitosan (derived from chitin and is also used in the thermogels), and providing analytical services to support Ultrasan.

Ferring Pharmaceuticals is owned by Swiss drugmaker Ferring Group, which was founded in 1951 and expanded into the US in the early 1980s. Ferring Pharmaceuticals knows that birthing babies is hard work. The company develops and markets a variety of fertility products, including hormone treatments Bravelle, Menopur, Novarel, and Repronex. The company also develops and manufactures products to diagnose and treat ailments in the areas of urology, endocrinology, osteoarthritis, and gastroenterology, including Euflexxa for osteoarthritis of the knee, Prosed for lower urinary tract infections, and Acthrel, a diagnostic agent for Cushing's syndrome.

Metabolex, Inc. was founded in 1991 and is based in Hayward, California. Metabolex, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of type II diabetes and related metabolic disorders. The company’s products include MBX-102/JNJ 39659100, an oral small-molecule insulin sensitizer; MBX-8025, which is intended for the treatment of dyslipidemia; MBX-2982, which is an agonist of GPR119, a G-protein coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract; and MBX-2044, a second generation insulin sensitizer.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.